Alnylam Pharmaceuticals
ALNY
653 hedge funds and large institutions have $43.1B invested in Alnylam Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 96 funds opening new positions, 262 increasing their positions, 217 reducing their positions, and 63 closing their positions.
52% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 63
24% more capital invested
Capital invested by funds: $34.8B → $43.1B (+$8.24B)
21% more repeat investments, than reductions
Existing positions increased: 262 | Existing positions reduced: 217
4% more funds holding
Funds holding: 626 → 653 (+27)
1.8% more ownership
Funds ownership: 99.53% → 101.33% (+1.8%)
8% less call options, than puts
Call options by funds: $188M | Put options by funds: $203M
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$165M |
| 2 |
Holocene Advisors
New York
|
+$165M |
| 3 |
ClearBridge Investments
New York
|
+$152M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$146M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$137M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$177M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$173M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$148M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$99.7M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$89.2M |
ALNY Hedge Fund Activity: Q2 2025 in Review
653 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2025, worth a combined $43.1B — up 24% from $34.8B a quarter earlier.
Buyers outnumbered sellers: 96 funds opened new ALNY positions and 63 closed out — a net gain of 33 holders — while 262 added to existing stakes and 217 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $165M. The largest seller was AQR Capital Management, cutting an estimated $177M.
- 653 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2025, up from 626 in Q1 2025.
- Funds reported $43.1B of Alnylam Pharmaceuticals stock for Q2 2025, up 24% quarter-over-quarter.
- 96 funds opened new Alnylam Pharmaceuticals positions in Q2 2025 and 63 closed out, a net change of +33 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2025 was Citadel Advisors, an estimated $165M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2025 was AQR Capital Management, an estimated $177M sold.
Based on aggregated 13F filings for Q2 2025.